| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From University of Calgary (O.S.), Calgary, AB, Canada; University of Kansas (G.G.), Kansas City; Division of Radiation Sciences (J.P.), Saint Louis, MO; University of Maryland Hospital (S.R.), Baltimore; Movement Disorder Center (T.Z.), Tampa, FL; and University of Maryland School of Medicine (W.J.W.), Baltimore.
Abstract-- Objective: To define key issues in the management of Parkinson disease (PD) relating to neuroprotective strategies and alternative treatments, and to make evidence-based treatment recommendations. Methods: Two clinical questions were identified. 1) In a patient diagnosed with PD, are there any therapies that can slow disease progression? 2) Are there any nonstandard pharmacologic or nonpharmacologic therapies that have been shown to improve motor function in PD? Articles were classified according to a four-tiered level of evidence scheme. Recommendations were based on the evidence. Results and conclusions: 1. Levodopa does not appear to accelerate disease progression. 2. No treatment has been shown to be neuroprotective. 3. There is no evidence that vitamin or food additives can improve motor function in PD. 4. Exercise may be helpful in improving motor function. 5. Speech therapy may be helpful in improving speech volume. 6. No manual therapy has been shown to be helpful in the treatment of motor symptoms, although studies in this area are limited. Further studies using a rigorous scientific method are needed to determine efficacy of alternative therapies.
This article has been cited by other articles:
|
|
 |
|
  P. A. LeWitt MAO-B inhibitor know-how: Back to the pharm Neurology, April 14, 2009; 72(15): 1352 - 1357. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. LeWitt Levodopa for the Treatment of Parkinson's Disease N. Engl. J. Med., December 4, 2008; 359(23): 2468 - 2476. [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Weiner There Is No Parkinson Disease Arch Neurol, June 1, 2008; 65(6): 705 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Simonson, R. A Hauser, and A. H. Schapira Role of the Pharmacist in the Effective Management of Wearing-Off in Parkinson's Disease Ann. Pharmacother., November 1, 2007; 41(11): 1842 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Ahlskog Beating a dead horse: Dopamine and Parkinson disease Neurology, October 23, 2007; 69(17): 1701 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Ahlskog I can't get no satisfaction: Still no neuroprotection for Parkinson disease Neurology, October 9, 2007; 69(15): 1476 - 1477. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sapir, J. L. Spielman, L. O. Ramig, B. H. Story, and C. Fox Effects of Intensive Voice Treatment (the Lee Silverman Voice Treatment [LSVT]) on Vowel Articulation in Dysarthric Individuals With Idiopathic Parkinson Disease: Acoustic and Perceptual Findings J Speech Lang Hear Res, August 1, 2007; 50(4): 899 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Hass, M. A. Collins, and J. L. Juncos Resistance Training With Creatine Monohydrate Improves Upper-Body Strength in Patients With Parkinson Disease: A Randomized Trial Neurorehabil Neural Repair, March 1, 2007; 21(2): 107 - 115. [Abstract] [PDF]
|
|
|
|
|
|
E. B. Montgomery Jr, O. Suchowersky, and S. Reich Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, January 9, 2007; 68(2): 164 - 164. [Full Text] [PDF]
|
|
|
|
|
|
D. Aarsland, M. Emre, A. Lees, W. Poewe, C. Ballard, E. B. Montgomery, J. M. Miyasaki, and G. Gronseth Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, January 2, 2007; 68(1): 80 - 81. [Full Text] [PDF]
|
|
|
|
 |
|
 American Academy of Neurology Practice Parameters: Parkinson Disease Diagnosis and Treatment Journal Watch Neurology, August 1, 2006; 2006(801): 1 - 1. [Full Text]
|
|
|
|
|
|
R. L. Albin Practice Parameters for Parkinson disease: signposts for clinical research. Neurology, April 11, 2006; 66(7): 966 - 967. [Full Text] [PDF]
|
|
|
|
|
|
R. L. Albin Practice Parameters for Parkinson disease: signposts for clinical research. Neurology, April 11, 2006; 66(7): 966 - 967. [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
